Grant: Doctoral: Vanier Canada Graduate Scholarships
McMaster University
$150,000.00
Mechanistic investigation of thrombosis in childhood acute lymphoblastic leukemia and the establishment of model to study potential therapeutic strategies
EF 2022-23
Résumé
Acute lymphoblastic leukemia (ALL) is a serious public health problem in the pediatric population affecting 1 in 1,500 children worldwide, and contributes to 85% of deaths from childhood cancer. It is an aggressive fast-growing cancer of white blood cells that gets worse quickly if left untreated. Blood clot is a well-recognized complication and the second leading cause of death in childhood ALL. Children with leukemia who developed blood clots had to withhold or delay cancer therapy, which explains their significantly worse overall survival rate, compared to patients without clots. Although modern treatment protocols can effectively eradicate the leukemia and the child are expected to live several decades, blood clots lead to significant long-term physical, psychosocial and financial burden. Mechanisms underlying the development of blood clots in ALL are multi-factorial and not well-understood. The cancer itself, chemotherapy and individual patient characteristics can all contribute to the risk of developing blood clots.
Understanding the biology of the disease is crucial for defining optimal strategy for prevention and management of ALL-associated blood clots. The public health's fundamental principle of "prevention is better than cure" drives our motivation to identify the root cause of blood clots in ALL. In this project, I will explore clots in ALL based on three board categories of contributing factors: Endothelial dysfunction, Hypercoagulability and Hemodynamic changes. Briefly, a co-culture model between healthy endothelium and donor leukemic blasts will be employed to evaluate the cell-to-cell interactions and how a prothrombotic environment is being promoted. Then, an animal model of blood clots in ALL will be established to identify potential preventative strategies. Overall, these findings will aid in preventing blood clots at the first place as well as highlighting therapeutic targets for thrombosis control in patients with ALL.
Programme
Doctoral: Vanier Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
474556
Name
Tieu Thuan Minh
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Circulatory and Respiratory Health
Theme2
Biomedical
Prcname2
Vanier Canada Graduate Scholarships CIHR
Projecttitle
Mechanistic investigation of thrombosis in childhood acute lymphoblastic leukemia and the establishment of model to study potential therapeutic strategies
Programtype2
Studentship Programs
Orgnameinp2
McMaster University
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
Doctoral: Vanier Canada Graduate Scholarships
Keyworddelim
Chemotherapy; Hematology; Leukemia; Pediatrics; Prophylactic Anticoagulation; Thrombosis
Abstract
Acute lymphoblastic leukemia (ALL) is a serious public health problem in the pediatric population affecting 1 in 1,500 children worldwide, and contributes to 85% of deaths from childhood cancer. It is an aggressive fast-growing cancer of white blood cells that gets worse quickly if left untreated. Blood clot is a well-recognized complication and the second leading cause of death in childhood ALL. Children with leukemia who developed blood clots had to withhold or delay cancer therapy, which explains their significantly worse overall survival rate, compared to patients without clots. Although modern treatment protocols can effectively eradicate the leukemia and the child are expected to live several decades, blood clots lead to significant long-term physical, psychosocial and financial burden. Mechanisms underlying the development of blood clots in ALL are multi-factorial and not well-understood. The cancer itself, chemotherapy and individual patient characteristics can all contribute to the risk of developing blood clots.
Understanding the biology of the disease is crucial for defining optimal strategy for prevention and management of ALL-associated blood clots. The public health's fundamental principle of "prevention is better than cure" drives our motivation to identify the root cause of blood clots in ALL. In this project, I will explore clots in ALL based on three board categories of contributing factors: Endothelial dysfunction, Hypercoagulability and Hemodynamic changes. Briefly, a co-culture model between healthy endothelium and donor leukemic blasts will be employed to evaluate the cell-to-cell interactions and how a prothrombotic environment is being promoted. Then, an animal model of blood clots in ALL will be established to identify potential preventative strategies. Overall, these findings will aid in preventing blood clots at the first place as well as highlighting therapeutic targets for thrombosis control in patients with ALL.
Competitiondate
202211
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Tieu, Thuan Minh
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $150,000~ $0~